Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers

In English

Författare

  • Jan Ottervald
  • Bo Franzen
  • Kerstin Nilsson
  • Lars I. Andersson
  • Mohsen Khademi
  • Bodil Eriksson
  • Sven Kjellstrom
  • György Marko-Varga
  • Ákos Végvári
  • Robert A. Harris
  • Thomas Laurell
  • Tasso Miliotis
  • Darius Matusevicius
  • Hugh Salter
  • Mats Ferm
  • Tomas Olsson
Visa allt

Summary, in English

Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved.

Publiceringsår

2010

Språk

Engelska

Sidor

1117-1132

Publikation/Tidskrift/Serie

Journal of Proteomics

Volym

73

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Medical Engineering

Nyckelord

  • Treatment
  • Prognosis
  • Biomarkers
  • Proteomics
  • Multiple sclerosis
  • CSF

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1874-3919